论文部分内容阅读
老年结肠癌患者的辅助治疗仍然有争议。Mayer B等就辅助治疗对年轻(<70岁)和老年(≥70岁)患者的益处进行探讨。年轻患者653例,老年患者202例。辅助化疗方案为单用5-FU、5-FU联合亚叶酸钙及5-FU联合α-干扰素。用患者生存时间与预期剩余寿命比(QSL)以及多变量Cox比例风险模型对预后进行分析。年轻患者和老年患者的8年总生存率分别为58.3%和57.4%。在老年患者中,单用5-FU、5-FU联合亚叶酸钙及5-FU联合α-干扰素辅助化疗相应的8年总生存率分别为
Adjuvant treatment of elderly patients with colon cancer remains controversial. Mayer B et al discuss the benefits of adjuvant therapy for young (<70 years old) and elderly (> 70 years old) patients. 653 young patients, 202 elderly patients. The adjuvant chemotherapy regimen consisted of 5-FU alone, 5-FU plus leucovorin and 5-FU plus a-interferon. Prognosis was analyzed using a patient-to-life-to-expected residual life ratio (QSL) and a multivariate Cox proportional hazard model. The 8-year overall survival rates for young patients and elderly patients were 58.3% and 57.4%, respectively. In elderly patients, the corresponding 8-year overall survival rates of 5-FU alone, 5-FU plus leucovorin and 5-FU plus a-interferon-adjuvant chemotherapy were